Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms

Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation -   Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in patients with high-risk MDS and AML -   Safety and efficacy data for Kymriah (tisagenlecleucel)* in real-world setting compared to pivotal trials in relapsed/refractory ALL and DLBCL -   Adakveo (crizanlizumab) post-hoc analyses of hospitalization data from the SUSTAIN study and interim data from the global SWAY survey in SCD - Basel, December 2, 2019 - Novartis looks forward to presenting data from the company's expansive hematology portfolio at the upcoming 61st American Society of Hematology Annual Meeting & Exposition (ASH), taking place December 7-10 in Orlando, Florida. More than 140 abstracts will be presented, demonstrating our growing pipeline of differentiated immunotherapies and our bold ambition to research and develop medicines that transform the standard of care for patients. "Our data at ASH are evidence of the hard work, dedication and pioneering mindset of our teams. Novartis is deeply committed to build on its deep legacy in hematology to provide new innovative treatments and solutions that help people with malignant and benign blood disorders live longer, better lives," said Susanne Schaffert, PhD, President, Novartis Oncology.